A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. by Mangiacapra F et al.
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Objectives This study sought to validate the ability of the VerifyNow P2Y12 assay (Accumetrics, San
Diego, California) in predicting both ischemic and bleeding events after elective percutaneous coro-
nary intervention (PCI).
Background High and low levels of platelet reactivity are associated with ischemic and bleeding
events, respectively, after PCI.
Methods A total of 732 patients on dual antiplatelet therapy undergoing elective PCI were re-
cruited. Platelet reactivity was measured before PCI. The primary endpoint was the 30-day incidence
of net adverse clinical events (NACE), deﬁned as the occurrence of ischemic or bleeding events, in
relation to P2Y12 reaction unit (PRU) distribution.
esults At receiver-operating characteristic curve analysis, PRU values could signiﬁcantly discriminate
etween patients with and without bleeding events (area under the curve [AUC]: 0.72; 95% conﬁdence
nterval [CI]: 0.65 to 0.80; p  0.0001) and those with and without ischemic events (AUC: 0.68; 95% CI:
.61 to 0.76; p  0.0001). The optimal cutoffs for bleeding (PRU 178) and ischemic events
PRU 239) were used to deﬁne 3 groups: low platelet reactivity (LPR) (LPR  PRU 178), normal plate-
et reactivity (NPR) (NPR  PRU 179 to 238), and high platelet reactivity (HPR) (HPR  PRU 239). The
ncidence of NACE was 14.1% in the LPR group, 7.8% in the NPR group (p  0.025 vs. LPR group), and
5.4% in the HPR group (p  0.005 vs. NPR group). At multivariate analysis, PRU values in the NPR
roup were an independent predictor of reduced risk of 30-day NACE (odds ratio: 0.47, 95% CI: 0.27
o 0.81).
onclusions A therapeutic window for platelet reactivity measured with the VerifyNow P2Y12 assay
an be identiﬁed using speciﬁc thresholds that deﬁne a group of patients at lower risk for both
schemic and bleeding events. Adjunctive measures may be beneﬁcial in patients with higher or
ower platelet reactivity in order to improve clinical outcomes after PCI. (J Am Coll Cardiol Intv
012;5:281–9) © 2012 by the American College of Cardiology Foundation
From the *Department of Cardiovascular Sciences, Campus Bio-Medico University, Rome, Italy; and the †Cardiovascular Center
Aalst, Aalst, Belgium. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.Manuscript received September 14, 2011; revised manuscript received January 9, 2012, accepted January 18, 2012.
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282Dual antiplatelet therapy with aspirin and clopidogrel is
a cornerstone of the pharmacological treatment of pa-
tients with coronary artery disease undergoing elective
percutaneous coronary intervention (PCI). However, a
wide interindividual variability in response to clopidogrel
therapy has been described (1– 4), implying that a sub-
stantial proportion of patients have inadequate platelet
inhibition (either too high or too low) at the time of PCI.
See page 290
In patients with a decreased response to clopidogrel, high
platelet reactivity (HPR) may re-
sult in increased risk of throm-
botic complications after PCI (5–
11). On the other hand, in patients
with increased response to clopi-
dogrel, low platelet reactivity
(LPR) may result in increased risk
of bleeding complications (12,13).
Various attempts have been
made to identify patients with inad-
equate platelet reactivity through
the use of different platelet function
tests (14,15). Using the VerifyNow
P2Y12 assay (Accumetrics, San Di-
ego, California), several studies
have shown that platelet reactivity
above a threshold of 240 P2Y12
reaction units (PRU) is associated
with an increase in both short-
and long-term ischemic adverse
events (8,9,11,16,17), whereas
PRU values 189 are associated
with higher risk of early major
bleeding or entry-site complications
after PCI (13). Overall, these data
suggest the possibility of iden-
tifying a therapeutic window for
platelet reactivity, measured with
the VerifyNow P2Y12 assay, as-
sociated with the lowest risk for
oth thrombotic and bleeding complications.
Therefore, we aimed to validate the ability of the
erifyNow P2Y12 assay in predicting both ischemic and
leeding events after elective PCI in patients on dual
ntiplatelet therapy.
ethods
Patient population and study design. The ARMYDA-
ROVE (Antiplatelet therapy for Reduction of MYocardial
amage during Angioplasty–Platelet Reactivity for Outcome
Abbreviations
and Acronyms
AUC  area under the curve
CI  confidence interval
HPR  high platelet
reactivity
LPR  low platelet reactivity
MI  myocardial infarction
NACE  net adverse clinical
event(s)
NPR  normal platelet
reactivity
NPV  negative predictive
value
OR  odds ratio
PCI  percutaneous
coronary intervention
PPV  positive predictive
value
PRU  P2Y12 reaction units
ROC  receiver-operating
characteristic
ST  stent thrombosis
TIMI  Thrombolysis In
Myocardial Infarction
TVR  target vessel
revascularizationalidation Effort) is a prospective study enrolling consecutiveatients with stable angina and established coronary artery
isease undergoing elective PCI from April 2010 to February
011 at the Department of Cardiovascular Sciences, Cam-
us Bio-Medico University, Rome, Italy, and at the Car-
iovascular Center Aalst, Aalst, Belgium. All patients re-
eived clopidogrel, either a 600-mg loading dose 6 h
efore intervention or a maintenance dose of 75 mg/day for
t least 5 days. Patients on chronic treatment did not receive
ny further loading dose of clopidogrel. Technicalities of the
rocedure, including use of the radial approach, drug-
luting stents, and glycoprotein IIb/IIIa inhibitors, were left
o the operator’s discretion. Procedural anticoagulation con-
isted of unfractionated heparin administrated to achieve an
ctivated clotting time of 250 to 300 s. Procedural success
as defined as a reduction in percent diameter stenosis to
elow 30% in the presence of Thrombolysis In Myocardial
nfarction (TIMI) flow grade 3 in the main vessel and all
ide branches 2 mm in diameter. After PCI, patients
eceiving bare-metal stents received clopidogrel 75 mg/day
or at least 4 weeks, whereas those receiving drug-eluting
tents received clopidogrel for 12 months. All patients were
n aspirin treatment before intervention and continued
spirin (80 to 100 mg/day) indefinitely. Exclusion criteria
ere upstream use of glycoprotein IIb/IIIa inhibitors, treat-
ent with oral anticoagulant drugs, platelet count 70 
09/l, high bleeding risk (active internal bleeding, history of
hemorrhagic stroke, intracranial neoplasm, arteriovenous
malformation or aneurysm, ischemic stroke in the previous
3 months), coronary artery bypass surgery in the previous 3
months, and severe renal failure (serum creatinine 2
mg/dl). After PCI, patients receiving bare-metal stents
received clopidogrel 75 mg/day for at least 4 weeks, whereas
those receiving drug-eluting stents received clopidogrel for
at least 12 months. Clinical follow-up data were obtained at
30 days following an office visit, a telephone interview, or
after chart review. All events were classified and adjudicated
by a physician not involved in the follow-up process. This
study complied with the Declaration of Helsinki and was
approved by the local ethics committees, with all patients
giving written informed consent.
Blood sampling and platelet function analysis. Platelet reac-
tivity was measured in the catheterization laboratory using
the VerifyNow P2Y12 assay immediately before PCI. Blood
was drawn from the femoral or radial artery immediately
after sheath insertion. After discarding the first 5 ml of
blood, a further sample was collected into a 2-ml tube
containing 3.2% sodium citrate. The VerifyNow P2Y12
assay is a validated optical turbidimetric point-of-care assay
specifically assessing the effects of P2Y12 receptor blockers
(18,19). Results are expressed as PRU: the lower the PRU
value, the higher the platelet aggregation inhibition, and
vice versa. In all cases, the operators were blinded to the
results of the platelet function analysis.
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283Blood samples were drawn before, at 8 and 24 h after
intervention for the assessment of creatine kinase-myocardial
band (CK-MB), and thereafter if clinically indicated. Mea-
surements of CK-MB levels were performed by Access 2
Immunochemiluminometric assay (Beckman Coulter, Fuller-
ton, California), and the upper limit of normal was 4 ng/ml.
Endpoints and deﬁnitions. The primary endpoint of this
study was the 30-day incidence of net adverse clinical events
(NACE), defined as the occurrence of ischemic events or
bleeding events, in relation to the PRU distribution. To
evaluate the impact of pre-PCI platelet aggregation on the
primary outcome measure, we stratified the study popula-
tion according to their platelet aggregation value using
cutoff points derived from receiver-operating characteristic
(ROC) curve analysis. Patients with PRU values below the
optimal cutoff for bleeding events were classified as having
LPR; patients with PRU values above the optimal cutoff for
ischemic events were classified as having HPR; the remain-
ing patients with PRU values between the aforementioned
cutoff point were classified as having normal platelet reac-
tivity (NPR).
Secondary endpoints were: 1) the occurrence of the single
components of the primary endpoint in relation to the PRU
distribution; and 2) platelet reactivity according to the occurrence
of outcome measures.
Ischemic events were defined as death, myocardial infarc-
tion (MI), or target vessel revascularization (TVR). MI included
both periprocedural and spontaneous events. Periprocedural
MI was defined as a post-procedural increase in CK-MB
3 times the 99th percentile of the upper reference limit for
Figure 1. Distribution of Platelet ReactivityPRU  P2Y12 reaction units.patients with baseline negative myocardial necrosis markers,
according to the Joint European Society of Cardiology/
American College of Cardiology Foundation/American Heart
Association/World Heart Federation task force consensus
statement on the redefinition of MI for clinical trials on
coronary intervention (20). In patients with increased base-
line levels of CK-MB, a subsequent increase 50% the
baseline value fulfilled the criteria for periprocedural MI
(21). Occurrence of spontaneous MI, defined as the pres-
ence of symptoms compatible with recurrent ischemia
associated with electrocardiographic changes indicative of
new ischemia (new ST-T changes or new left bundle branch
block) (20) was also registered. Definite stent thrombosis
(ST) was defined according to the Academic Research
Consortium definition (22). TVR was clinically driven and
included bypass surgery or repeat PCI of the target vessel(s).
Bleeding events were defined as major bleeding according to
the TIMI criteria (23), or large entry-site hematoma (10
cm in diameter) (13). Entry-site hematomas were repeatedly
monitored throughout the hospitalization, and the largest
size detected was used for the analysis.
Statistics. In the ARMYDA-PRO (Antiplatelet therapy for
eduction of MYocardial Damage during Angioplasty-
latelet Reactivity Predicts Outcome) study (9), the 30-day
ncidence of ischemic events in patients with PRU values
240 was 15.0%, whereas in the ARMYDA-BLEEDS
Antiplatelet Therapy for Reduction of Myocardial Damage
uring Angioplasty-Bleeding Study) (13), the 30-day inci-
ence of bleeding events was 11.6% in patients with
re-PCI PRU values 189. Assuming that patients falling
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284in the NPR group represent one-third of the entire popu-
lation, and expecting in these patients a 50% reduction in
the occurrence of NACE, compared with patients in the
LPR and HPR groups, a total of at least 700 patients were
needed to detect the expected difference with an estimated
power of 80% at a 2-sided alpha of 0.05.
Continuous variables are expressed as mean  SD or as
median [interquartile range], as appropriate, whereas cate-
gorical variables are reported as frequencies and percentages.
Comparisons between continuous variables were performed
using the Student t test or Mann-Whitney U test. Com-
parisons between categorical variables were evaluated using
the Fisher exact test or the Pearson chi-square test, where
appropriate. Normal distribution of PRU levels in the study
population was confirmed by Kolmogorov-Smirnov test. A
ROC curve analysis was used to test the ability of PRU
values to discriminate between patients with and without
ischemic events, and with and without bleeding events at 30
days. The optimal cutoff point was calculated by determin-
ing the value that provided the greatest sum of sensitivity
Table 1. Clinical Characteristics
Overall Pop
(N  73
Age, yrs 66 1
Male 536 (73
Body mass index, kg/m2 25.9 3
Diabetes mellitus 216 (30
Hypertension 570 (78
Hyperlipidemia 552 (75
Current smoker 145 (20
Previous myocardial infarction 220 (30
Previous coronary intervention 244 (33
Previous bypass surgery 36 (5)
Left ventricular ejection fraction, % 56 7
Left ventricular ejection fraction 40% 56 (8)
White blood cells, 1,000/mm3 8.1 3
C-reactive protein, mg/l 2.5 [1.2–
Total cholesterol, mg/dl 170 4
Low-density lipoprotein cholesterol, mg/dl 97 3
Creatinine, mg/dl 1.08 0
Chronic renal failure 99 (14
Multivessel disease 312 (43
Clopidogrel regimen
Loading dose, 600 mg 644 (88
Maintenance dose, 75 mg 5 days 88 (12
Baseline medications
Aspirin 732 (10
Statin 651 (89
Calcium-channel blocker 168 (23
Proton pump inhibitor 249 (34
PRU 206 7
Values are mean SD, n (%), or median [interquartile range].HPR high platelet reactivity; LPR low platelet reactivity; NPR normaand specificity. All clinical and procedural features, as well
as pre-PCI platelet reactivity groups, were evaluated in a
univariate analysis for the association with 30-day NACE
using logistic regression. Only variables with a p value 0.15
ere then entered into the final multivariable logistic
egression model providing odds ratios (ORs) and 95%
onfidence intervals (CI). Statistical analysis was performed
sing Stata/IC version 10.0 (STATA Corp., College Sta-
ion, Texas), and p values 0.05 (2-tailed) were considered
ignificant.
esults
Study population. A total of 732 patients were recruited
nto the study. The distribution of platelet reactivity is
hown in Figure 1. Clinical and procedural features are
isted in Tables 1 and 2, respectively. Diabetes mellitus was
ore frequent among patients with HPR, who also more
requently had multivessel disease. Procedural success was
chieved in all patients. In 23 patients, a flow-limiting vessel
LPR
(n  248)
NPR
(n  244)
HPR
(n  240) p Value
66 10 66 9 67 10 0.201
176 (71) 178 (73) 182 (76) 0.476
25.6 3.2 26.0 3.0 26.1 3.3 0.181
55 (22) 70 (29) 91 (38) 0.001
192 (77) 190 (78) 188 (78) 0.971
180 (73) 185 (76) 187 (78) 0.386
57 (23) 44 (18) 44 (18) 0.303
81 (33) 68 (29) 71 (30) 0.501
84 (34) 90 (37) 70 (29) 0.193
10 (4) 12 (5) 14 (6) 0.743
56 8 56 7 55 7 0.804
25 (10) 15 (6) 16 (7) 0.106
8.3 3.5 7.9 3.6 8.2 3.1 0.407
2.3 [1.0–5.9] 2.5 [1.1–6.8] 2.5 [1.3–7.3] 0.217
169 52 175 57 168 47 0.315
97 29 95 32 101 33 0.103
1.08 0.26 1.08 0.24 1.10 0.29 0.530
27 (11) 37 (15) 35 (15) 0.321
93 (38) 102 (42) 117 (49) 0.041
0.922
219 (88) 213 (87) 212 (88)
29 (12) 31 (13) 28 (12)
248 (100) 244 (100) 240 (100) 1.000
218 (89) 215 (88) 218 (91) 0.518
53 (21) 58 (24) 57 (24) 0.767
87 (35) 84 (34) 78 (33) 0.823
127 35 206 17 287 38 0.001ulation
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2l platelet reactivity; PRU P2Y12 reaction units.
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285dissection occurred after stent implantation and was suc-
cessfully treated with the implantation of an additional stent
in all cases. A total of 9 patients had no-reflow phenomenon
(TIMI flow grade 2 not attributable to dissection, occlu-
sive thrombosis, or epicardial spasm), which significantly
improved in all cases after administration of intracoronary
nitrates, adenosine, and glycoprotein IIb/IIIa inhibitors. No
evident vessel or side-branch (2 mm) closure occurred.
Bailout use of glycoprotein IIb/IIIa inhibitors was low, as
was the use of radial access.
Primary endpoint. No patients were lost at 30-day follow-
p. A total of 57 (7.8%) ischemic events and 36 (4.8%)
leeding events occurred. Ischemic events included 3
eaths, 51 MI (45 periprocedural and 6 spontaneous, of
hich 4 were due to ST), and 6 TVR. The sources of major
leeding were genitourinary in 4 patients, gastrointestinal in
patients, and cerebral in 1 patient. Twenty-seven patients
ad entry-site hematoma 10 cm. In 2 patients, both an
schemic (MI) and a bleeding event (entry-site hematoma
10 cm) occurred. A total of 91 (12.3%) patients experi-
nced at least 1 NACE.
ROC curve analysis demonstrated that pre-PCI PRU
alues could significantly discriminate between patients with
nd without ischemic events (area under the curve [AUC]:
.68; 95% CI: 0.61 to 0.76; p  0.0001). A PRU value
239 was the optimal cutoff point to predict ischemic
vents, with a sensitivity of 63%, specificity of 70%, a
egative predictive value (NPV) of 96%, and a positive
Table 2. Procedural Characteristics
Overall Pop
(N  7
Treated vessel
Left main 3 (1
Left anterior descending 407 (5
Left circumﬂex 136 (1
Right coronary artery 182 (2
Saphenous vein graft 3 (1
Lesion type B2/C 425 (5
Multivessel intervention 106 (1
Use of stent 706 (9
Use of drug-eluting stent 201 (2
Stents implanted, n 1.41 0
Total stent length, mm 18 [15–
Maximal inﬂation pressure, atm 15 2
Side-branch occlusion 11 (2
Radial access 29 (4
Sheath size
6-F 681 (9
7-F 51 (7
Bailout use of glycoprotein IIb/IIIa inhibitors 44 (6
Values are n (%), mean SD, or median [interquartile range].
Abbreviations as in Table 1.redictive value (PPV) of 15% (Fig. 2A). Similarly, pre-PCIRU values could significantly discriminate between pa-
ients with and without bleeding events (AUC: 0.72; 95%
I: 0.65 to 0.80; p  0.0001). A PRU value 178 was the
ptimal cutoff point to predict bleeding events, with a
ensitivity of 78%, specificity of 63%, a NPV of 98%, and a
PV of 10% (Fig. 2B). On the basis of these results, we
ivided our study population into 3 groups based on the
istribution of PRU values: LPR (PRU 178; n  248
33.9%]), NPR (PRU between 179 and 238; n  244
33.3%]), and HPR (PRU 239; n  240 [32.8%]).
The incidence of NACE was 14.1% in the LPR group,
.8% in the NPR group (p  0.025 vs. LPR group), and
5.4% in the HPR group (p  0.005 vs. NPR group)
Fig. 3). Considering patients with LPR and HPR together,
he incidence of NACE was 14.8% (p  0.007 vs. NPR
roup). PRU values in the LPR or HPR group could predict
he occurrence of NACE with a sensitivity of 79%, a
pecificity of 35%, a NPV of 92%, a PPV of 15%, and an
verall prognostic accuracy of 41%.
Secondary endpoints. Patients in the LPR, NPR, and HPR
roups presented an incidence of ischemic events of 4.0%,
.9%, and 15.0%, respectively (p for trend 0.0001)
(Fig. 4A), and an incidence of bleeding events of 10.5%,
2.9%, and 1.3%, respectively (p for trend 0.0001)
(Fig. 4B). The incidence of the single components of the
primary endpoint according to PRU groups is reported in
Figure 4. The incidence of death was overall low and similar
in the 3 study groups (0.4%). Patients in the HPR group
n LPR
(n  248)
NPR
(n  244)
HPR
(n  240) p Value
0.189
1 (1) 1 (1) 1 (1)
123 (50) 143 (58) 141 (59)
56 (22) 45 (18) 35 (14)
67 (26) 55 (22) 60 (25)
1 (1) 1 (1) 1 (1)
146 (59) 137 (56) 142 (59) 0.758
30 (12) 33 (14) 43 (18) 0.165
239 (96) 234 (96) 233 (97) 0.779
78 (31) 67 (27) 56 (23) 0.133
1.34 0.83 1.42 0.80 1.47 0.98 0.252
18 [15–24] 18 [15–32] 18 [13–30] 0.760
15 2 15 3 15 2 0.893
3 (1) 4 (2) 4 (2) 0.897
12 (5) 8 (3) 9 (4) 0.661
0.799
231 (93) 225 (92) 225 (94)
17 (7) 19 (8) 15 (6)
19 (7) 11 (5) 14 (6) 0.335ulatio
32)
)
5)
8)
5)
)
8)
4)
6)
7)
.86
30]
)
)
3)
)
)showed the highest incidence of MI (p for trend 0.001)
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286and TVR (p for trend  0.041). Periprocedural MI occurred
n 3.2%, 4.5%, and 13.3% of patients with LPR, NPR, and
PR, respectively (p for trend 0.001). Spontaneous MI
ccurred in 0.4%, 0.0%, and 2.1% of patients with LPR, NPR,
nd HPR, respectively (p for trend 0.041). ST occurred in 4
atients (1.7%) in the HPR group and in none of the LPR or
PR groups (p for trend 0.013). Patients in the LPR group
howed the highest incidence of major bleeding (p for trend
.003) and hematoma 10 cm (p for trend 0.001).
The average pre-PCI platelet reactivity was 207  73
RU in the overall population, and 206  72 PRU in
atients without adverse events at 30-day follow-up. Pa-
ients experiencing bleeding events had the lowest PRU
alues (154  59, p  0.0001 vs. patients without events),
hereas patients experiencing ischemic events had the
ighest PRU values (247  67, p  0.0001 vs. patients
ithout events) (Fig. 5).
Multivariate analysis. At univariate analysis, diabetes melli-
tus, multivessel disease, chronic renal failure, total stent
length, use of glycoprotein IIb/IIIa inhibitors, and PRU
Figure 2. ROC Curves for PRU Values
(A) Receiver-operating characteristic (ROC) analysis for ischemic events. (B)
ROC analysis for bleeding events. PRU values are in the opposite direction
for the 2 curves. AUC  area under the curve; CI  conﬁdence interval;
NPV  negative predictive value; PPV  positive predictive value; PRU 
P2Y12 reactivity unit.values in the NPR range were significantly associated withthe occurrence of NACE. Multivariate analysis (Table 3)
showed that PRU values in the NPR range were an
independent predictor of decreased risk of NACE (OR:
0.47, 95% CI: 0.27 to 0.81).
Discussion
In the present study, we have identified a therapeutic window
for platelet reactivity, as measured by the VerifyNow P2Y12
assay, in patients with stable angina undergoing elective PCI.
Those patients with PRU values within this therapeutic win-
dow accounted for one-third of our patients and had the lowest
risk for the combined endpoint of ischemic and bleeding
complications, 30 days after elective PCI. Of note, PRU
values between 179 and 238 resulted in almost a 50% risk
reduction for NACE compared with patients with either
low or high platelet reactivity.
Given the wide interindividual variability in response to
clopidogrel (4), platelet reactivity is highly heterogeneous in
the overall population of patients on dual antiplatelet therapy,
and follows a normal Gaussian distribution (Fig. 1). Therefore,
it ranges from low levels on one extreme of its bell-shaped
distribution to high levels on the other extreme. Several
studies have shown that patients who have high platelet
reactivity before PCI are at increased risk of ischemic events
despite taking dual antiplatelet therapy (5–11). Several
attempts have been made to identify optimal thresholds of
platelet reactivity in order to stratify those patients at risk of
ischemic events following PCI (14,15). Among the many
commercially available platelet function tests, the VerifyNow
P2Y12 assay has proven to be particularly useful. Not only
is it an effective tool for identifying high platelet reactivity in
patients taking dual antiplatelet therapy using a threshold of
240 PRU, but knowing this information helps to predict
which patients will experience an ischemic event
(8,9,11,16,17,24). Consistent with these studies, we also
found a very similar optimal cutoff value to predict ischemic
events in our population of patients undergoing elective PCI
Figure 3. Kaplan-Meier Curves for 30-Day NACE-Free Survival
HPR  high platelet reactivity; LPR  low platelet reactivity; NACE  net
adverse clinical event; NPR  normal platelet reactivity.
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287with a PRU value of 239. Our data also corroborate the
hypothesis that a threshold effect exists for ischemic events
(15,25). In fact, the incidence of ischemic events was similar
in patients with low and normal platelet reactivity, suggest-
ing that below the safety threshold of PRU, ischemic events
are not further significantly reduced.
In addition to that of recurrent ischemic events, the
prognostic importance of bleeding complications following
PCI has also been established. Ndrepepa et al. (26) have
shown that patients with bleeding events within 30 days
Figure 4. Single Components of the Primary Endpoint and Platelet Reactiv
Ischemic events (A) and bleeding events (B) according to P2Y12 reaction unit
TVR  target vessel revascularization; other abbreviations as in Figure 3.
Figure 5. Platelet Reactivity and Adverse Events
Boxes extend from the 25th to the 75th percentile, with a line at the 50th
percentile (median). Whiskers show the highest and the lowest value.
PRU  P2Y12 reaction units.after PCI have a 3-fold higher risk for 1-year mortality
compared with patients without bleeding. Moreover, in a
study of 6.995 patients undergoing PCI, periprocedural
bleeding complications were significantly associated with
increased risk for mortality and adverse cardiac events at
follow-up (27). Recently, 2 studies have sought to define
thresholds of platelet reactivity to identify patients at higher
risk for bleeding events after PCI. In 1 of these studies
enrolling patients undergoing PCI after a 600-mg clopi-
dogrel loading, increased platelet inhibition (188 aggre-
gation units), measured with multiple-electrode aggregom-
etry, resulted in a 3.5-fold higher in-hospital incidence of
major bleeding (12). Similarly, the ARMYDA-BLEEDS
study (13) showed that low residual platelet reactivity after
clopidogrel, as measured with the VerifyNow P2Y12 assay
before PCI, is associated with a significantly higher inci-
dence of 30-day major bleeding or entry-site complications,
also suggesting a threshold of PRU 189 as the optimal
cutoff to predict bleeding events. In the present study, we
confirm the predictive value of platelet reactivity, as mea-
sured with the VerifyNow P2Y12 assay, on the occurrence
of bleeding events after PCI, and we found that the optimal
cutoff to predict such events was a PRU value178. Similar
to ischemic events, a threshold effect seems to be present for
bleeding, as no significant difference in the incidence of
bleeding events was found between patients with normal
and high platelet reactivity.
Using the 2 thresholds for ischemic and bleeding events,
we have found a therapeutic window for platelet reactivity,
ranging from 179 to 238 PRU, which was associated with
the lowest incidence of net adverse events. Despite being
relatively small, this range accounts for one-third of the
overall population, whereas the remainder of patients was
equally distributed between the low and high platelet
reactivity groups (Fig. 1). Although the optimal cutoff for
s. *p for trend 0.001; **p for trend 0.05. MI  myocardial infarction;ity
groupischemic events (PRU 239) was very close to the one
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 3 , 2 0 1 2
M A R C H 2 0 1 2 : 2 8 1 – 9
Mangiacapra et al.
Therapeutic Window for Platelet Reactivity Pre-PCI
288described in ARMYDA-PRO (9) and other studies
(8,10,11), we found that the optimal cutoff to predict
bleeding (PRU 178) was lower than the one previously
described in ARMYDA-BLEEDS (PRU 189) (13). As
expected, the PPV for both the ischemic and bleeding
thresholds was very low (15% and 10%, respectively). As
predictive values of a test depend on the prevalence of the
tested condition, this could be partly explained with the
relatively low occurrence of adverse events in a low-risk
population of stable patients undergoing elective PCI.
Sibbing et al. (28) have also found a therapeutic window
for pre-PCI platelet reactivity, as measured with multiple-
electrode aggregometry, identifying the group of patients
with aggregation values in the range of 189 to 467 aggre-
gation units as having the lowest risk for the occurrence of
both bleeding and ischemic events. However, in this anal-
ysis, only in-hospital bleeding and 30-day ST were consid-
ered. Recently, Campo et al. (25) have also found a
therapeutic window for platelet reactivity measured with the
VerifyNow P2Y12 assay (between 86 and 238 PRU). However,
in this study, platelet reactivity was measured 30 days after
PCI, and the adverse events occurred within the first month
were excluded from the analysis. Moreover, a different
definition for bleeding events, including both TIMI and
BleedScore classifications, was used, compared with the
present study.
According to our results, pre-PCI evaluation of platelet
reactivity carries important prognostic information and may
guide the therapeutic approach to those patients that do not
fall within the described therapeutic window. In particular,
in patients with a low response to clopidogrel and higher
ischemic risk, more aggressive antiplatelet strategies might
be useful in obtaining platelet reactivity values that fall
within the desired range. These include higher clopidogrel
doses, the use of inducers of clopidogrel metabolism (i.e.,
cilostazol), or newer, more potent P2Y12 receptor blockers.
Although 1 recent study that did tailor antiplatelet therapy
by doubling the clopidogrel dose in patients with low
response using VerifyNow P2Y12 results did not show any
significant benefit (29), further studies are necessary to
Table 3. Univariate and Multivariate Predictors of Ne
Univa
OR [95% CI]
Normal platelet reactivity 0.49 [0.29–0.83]
Diabetes mellitus 1.52 [0.91–1.98]
Multivessel disease 1.39 [0.89–2.18]
Chronic renal failure 1.68 [1.02–3.36]
Total stent length 1.02 [1.01–1.04]
Glycoprotein IIb/IIIa inhibitors 2.20 [1.05–4.63]
CI confidence interval; OR odds ratio.clarify this issue (30). On the other hand, in patients withincreased response to clopidogrel and higher bleeding risk,
besides deferring PCI until platelet reactivity falls within the
desired range, individualized preventive measures could also
be indicated (i.e., restricted use of glycoprotein IIb/IIIa
inhibitors and drug-eluting stents, more extensive use of the
radial approach, bivalirudin, and gastroprotective agents).
Study limitations. By study design, we aimed to identify a
group of patients with intermediate platelet reactivity pre-
senting the lowest incidence of adverse clinical events
among our total population of patients undergoing PCI.
This approach implies that the set of patients used to test
the hypothesis corresponds to the validation set. The
absence of an independent validation set represents a limi-
tation of this study.
Conclusions
This study, using the VerifyNow P2Y12 assay, identified a
therapeutic window for platelet reactivity that defines a group
of patients at lower risk for both ischemic and bleeding events.
Adjunctive measures may be beneficial in patients with higher
or lower platelet reactivity in order to improve clinical out-
comes after PCI. Larger studies, possibly with longer follow-
up, are warranted to test this hypothesis.
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